エピジェネティクス診断市場 - 世界の産業規模、シェア、動向、機会、および予測、2018年～2028年製品別、用途別、技術別、地域別、競合別分析

世界のエピジェネティクス診断市場は、2022年に122億5,000万米ドルと評価され、2028年までのCAGRは7.25%で、予測期間中に着実な成長を予測されています。

進化し続けるヘルスケアの中で、最も有望で革新的な分野として脚光を浴びているのがエピジェネティクス診断です。エピジェネティクスは、基礎となるDNA配列に変更を加えることなく遺伝子発現や細胞表現型を変化させる研究であり、様々な疾患とその潜在的な診断・治療法に関する我々の理解に革命をもたらしました。世界のエピジェネティクス診断市場はこの変革の最前線にあり、個別化医療と疾病管理のための新たな道を提供しています。エピジェネティクスの修飾は、DNAやヒストン蛋白質に対する化学的変化を含み、遺伝子の活性に影響を及ぼします。これらの修飾は遺伝する可能性があり、環境要因の影響を受けるため、エピジェネティクスは遺伝と健康の関係を探求するダイナミックな分野となっています。

がん、心血管疾患、神経変性疾患などの慢性疾患の世界の負担は増加の一途をたどっています。エピジェネティクスの診断は、疾患の罹りやすさや進行に関する洞察を提供し、早期発見や個別化治療戦略を可能にします。ハイスループットシークエンシング、DNAメチル化解析、ヒストン修飾プロファイリングの進歩により、エピジェネティクス診断がより身近で費用対効果の高いものとなり、市場成長が加速しています。精密医療へのシフトは、個人のユニークな遺伝的およびエピジェネティックなプロファイルに合わせて治療を調整することを強調しています。エピジェネティクス診断は、適切な治療選択肢を特定する上で極めて重要な役割を果たします。世界人口の高齢化が進むにつれ、加齢関連疾患を予測・監視できる診断ツールの需要が高まっています。エピジェネティクスは、遺伝子発現における加齢関連の変化に関する貴重な洞察を提供します。

主な市場促進要因

複雑な疾患の発生率の増加がエピジェネティクス診断の世界市場を牽引

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 エピジェネティクス診断の世界市場展望

• 市場規模と予測
  • 金額別
• 市場シェアと予測
  • 製品別（試薬、キット（チップシーケンスキット、ホールゲノムアンプリフィケーションキット、バイサルファイト変換キット、RNAシーケンスキット、その他）、機器、酵素、サービス）
  • 用途別（がん（固形がん、その他）、非がん（炎症性疾患、代謝性疾患、感染症、循環器疾患、その他））
  • 技術別（DNAメチル化、ヒストンメチル化、ヒストンアセチル化、Large noncoding RNA、MicroRNA修飾）
  • 地域別
  • 企業別（2022年）
• 市場マップ
  • 製品別
  • 用途別
  • 技術別
  • 地域別

第5章 アジア太平洋のエピジェネティクス診断市場の展望

• 市場規模・予測
  • 金額別
• 市場シェアと予測
  • 製品別
  • 用途別
  • 技術別
  • 国別
• アジア太平洋：国別分析
  • 中国
  • インド
  • オーストラリア
  • 日本
  • 韓国

第6章 欧州のエピジェネティクス診断市場の展望

• 市場規模と予測
  • 金額別
• 市場シェアと予測
  • 製品別
  • 用途別
  • 技術別
  • 国別
• 欧州：国別分析
  • フランス
  • ドイツ
  • スペイン
  • イタリア
  • 英国

第7章 北米のエピジェネティクス診断市場の展望

• 市場規模・予測
  • 金額別
• 市場シェアと予測
  • 製品別
  • 用途別
  • 技術別
  • 国別
• 北米：国別分析
  • 米国
  • メキシコ
  • カナダ

第8章 南米のエピジェネティクス診断市場の展望

• 市場規模・予測
  • 金額別
• 市場シェアと予測
  • 製品別
  • 用途別
  • 技術別
  • 国別
• 南米：国別分析
  • ブラジル
  • アルゼンチン
  • コロンビア

第9章 中東・アフリカのエピジェネティクス診断市場の展望

• 市場規模・予測
  • 金額別
• 市場シェアと予測
  • 製品別
  • 用途別
  • 技術別
  • 国別
• 中東・アフリカ：国別分析
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • エジプト

第10章 市場力学

• 促進要因
• 課題

第11章 市場動向と発展

• 最近の動向
• 製品上市
• 合併と買収

第12章 エピジェネティクス診断の世界市場SWOT分析

第13章 ポーターのファイブフォース分析

• 業界内の競合
• 新規参入の可能性
• サプライヤーの力
• 顧客の力
• 代替品の脅威

第14章 競合情勢

• Roche Diagnostics
  • Business Overview
  • Company Snapshot
  • Products & Services
  • Current Capacity Analysis
  • Financials（In case of listed）
  • Recent Developments
  • SWOT Analysis
• Thermo Fisher Scientific, Inc.
• Eisai Co. Ltd.
• Novartis AG
• Element Biosciences, Inc.
• Dovetail Genomics LLC.
• Illumina, Inc.
• ValiRx Plc.
• Abcam plc.

第15章 戦略的提言

第16章 調査会社について・免責事項

Global Epigenetics Diagnostics Market has valued at USD 12.25 Billion in 2022 and is anticipated to project steady growth in the forecast period with a CAGR of 7.25% through 2028. In the ever-evolving landscape of healthcare, one of the most promising and innovative fields gaining prominence is epigenetics diagnostics. Epigenetics, the study of changes in gene expression or cellular phenotype without alterations to the underlying DNA sequence, has revolutionized our understanding of various diseases and their potential diagnostics and treatments. The Global Epigenetics Diagnostics Market is at the forefront of this transformation, offering new avenues for personalized medicine and disease management. Epigenetic modifications involve chemical alterations to DNA and histone proteins, which can influence gene activity. These modifications can be heritable and are influenced by environmental factors, making epigenetics a dynamic field for exploring the relationship between genetics and health.

The global burden of chronic diseases such as cancer, cardiovascular diseases, and neurodegenerative disorders is on the rise. Epigenetics diagnostics offer insights into disease susceptibility and progression, allowing for early detection and personalized treatment strategies. Advances in high-throughput sequencing, DNA methylation analysis, and histone modification profiling have made epigenetics diagnostics more accessible and cost-effective, accelerating market growth. The shift towards precision medicine emphasizes tailoring treatments to an individual's unique genetic and epigenetic profile. Epigenetics diagnostics play a crucial role in identifying suitable treatment options. As the global population continues to age, the demand for diagnostic tools that can predict and monitor age-related diseases is increasing. Epigenetics provides valuable insights into age-related changes in gene expression.

Key Market Drivers

Increasing Incidence of Complex Diseases is Driving the Global Epigenetics Diagnostics Market

The global healthcare landscape is witnessing a significant shift towards personalized medicine, and one of the key players in this transformation is epigenetics diagnostics. Epigenetics, the study of changes in gene expression that do not involve alterations to the underlying DNA sequence, has emerged as a critical field in understanding and treating complex diseases. As the incidence of these diseases continues to rise, the global epigenetics diagnostics market is experiencing substantial growth. Complex diseases, also known as multifactorial or polygenic diseases, are conditions that result from a combination of genetic, environmental, and lifestyle factors. Examples of complex diseases include cancer, cardiovascular diseases, diabetes, and neurological disorders like Alzheimer's and Parkinson's disease. These conditions are a significant burden on global healthcare systems, both in terms of healthcare costs and patient quality of life.

With the global population aging, there is a higher prevalence of age-related diseases, such as cancer and neurodegenerative disorders. Unhealthy lifestyle choices, such as poor diet, lack of physical activity, and smoking, contribute to the development of complex diseases like diabetes and cardiovascular conditions. Exposure to environmental toxins and pollutants can increase the risk of various diseases, including cancer. Genetic factors play a role in complex diseases, and individuals with a family history are at higher risk.

The increasing incidence of complex diseases is a global healthcare challenge, but epigenetics diagnostics offers promising solutions. As the field of epigenetics continues to evolve and provide deeper insights into disease mechanisms, the global epigenetics diagnostics market is expected to expand further. The ability to detect diseases earlier, tailor treatments to individual patients, and monitor treatment responses makes epigenetics diagnostics a vital tool in the fight against complex diseases, ultimately improving patient outcomes and reducing healthcare costs.

Increasing Pharmaceutical Research and Drug Development is Driving the Global Epigenetics Diagnostics Market

In recent years, pharmaceutical research and drug development have played a pivotal role in driving the global epigenetics diagnostics market. Pharmaceutical companies are increasingly incorporating epigenetic insights into their drug discovery processes. Understanding the epigenetic mechanisms involved in diseases has led to the development of targeted therapies that can modulate these mechanisms. For example, drugs targeting DNA methylation and histone modifications have shown promise in treating various cancers. Epigenetic biomarkers have become critical tools in diagnosing diseases and predicting treatment responses. Pharmaceutical research has focused on identifying and validating these biomarkers, enabling more accurate disease detection and personalized treatment plans. Pharmaceutical companies conduct clinical trials to assess the safety and efficacy of epigenetic drugs. These trials provide essential data that help bring epigenetic therapies to the market. As more epigenetic drugs advance through clinical trials, they contribute to the growth of the epigenetics diagnostics market.

Epigenetic drugs, such as DNA methyltransferase inhibitors and histone deacetylase inhibitors, have demonstrated effectiveness in treating various cancers. Their development has not only expanded treatment options but has also increased the demand for epigenetics diagnostics to guide patient selection and monitor treatment responses. Epigenetics diagnostics play a pivotal role in personalized medicine. By analyzing a patient's epigenetic profile, healthcare providers can tailor treatments to individual needs, maximizing therapeutic outcomes while minimizing side effects. This approach has the potential to transform healthcare and improve patient outcomes. Epigenetics diagnostics are not limited to disease diagnosis and treatment. They also hold promise in disease prevention and early intervention. Pharmaceutical companies are exploring the use of epigenetic markers to identify individuals at high risk for certain diseases, allowing for proactive measures to reduce disease incidence.

Key Market Challenges

Complexity of Epigenetic Modifications

Epigenetics is an intricate and dynamic field that involves the study of various modifications to DNA and associated proteins. These modifications, such as DNA methylation and histone acetylation, can be tissue-specific and context-dependent. Understanding the functional implications of these modifications and their relevance to disease requires extensive research and validation. Developing accurate diagnostic tests based on such complexity is a daunting task.

Lack of Standardization

One of the major challenges in the epigenetics diagnostics market is the lack of standardized protocols and methodologies for data collection and analysis. Different research groups and diagnostic companies may use varying techniques and platforms, leading to inconsistencies in results. Establishing standardized procedures is crucial to ensure the reliability and reproducibility of epigenetic diagnostic tests.

Data Interpretation and Analysis

Epigenetic data generated from diagnostic assays are often voluminous and require sophisticated computational tools for analysis. Interpreting these data in a clinically meaningful way poses a significant challenge. Additionally, translating research findings into actionable diagnostic information that healthcare professionals can use in patient care is an ongoing struggle.

Biomarker Discovery

Identifying reliable epigenetic biomarkers for specific diseases is a time-consuming and resource-intensive process. While promising candidates have been discovered for various conditions, including cancer and neurological disorders, validating their clinical utility is a complex task. Many potential biomarkers fail to withstand rigorous testing, hindering the development of effective diagnostic tests.

Ethical and Regulatory Issues

Epigenetic diagnostics raise ethical and regulatory concerns, particularly when it comes to privacy and consent. The sensitive nature of epigenetic information and the potential for misuse require careful consideration of ethical guidelines and regulatory frameworks. Balancing innovation with patient rights and privacy is an ongoing challenge.

Cost and Accessibility

High development and research costs associated with epigenetic diagnostics can limit their accessibility to a broader population. As new technologies emerge, ensuring that these tests are affordable and accessible to all socioeconomic groups is a crucial challenge.

Integration into Clinical Practice

For epigenetic diagnostics to make a significant impact on healthcare, they must be integrated seamlessly into clinical practice. This involves educating healthcare providers, demonstrating the clinical utility of these tests, and overcoming resistance to change within the medical community.

Key Market Trends

Technological Advancements

In the fast-paced world of healthcare, technological advancements play a pivotal role in enhancing our understanding of diseases and revolutionizing diagnostic and treatment approaches. One such field that has witnessed remarkable progress in recent years is epigenetics diagnostics. Epigenetics, the study of heritable changes in gene expression without alterations to the DNA sequence, has emerged as a promising avenue for diagnosing and understanding various diseases. Technological innovations have been the driving force behind the growth of the global epigenetics diagnostics market, offering new insights and tools for healthcare professionals.

DNA methylation, the addition of methyl groups to DNA molecules, is a crucial epigenetic modification. Advanced technologies like DNA methylation arrays and next-generation sequencing (NGS) have enabled researchers to profile methylation patterns across the entire genome quickly and cost-effectively. This has led to the discovery of methylation markers associated with various diseases, making them valuable diagnostic targets. Single-cell epigenomics technologies have allowed researchers to study epigenetic changes at the individual cell level. This advancement has proven crucial in understanding cellular heterogeneity within tissues, enabling more accurate disease characterization and diagnosis.

Liquid biopsies have gained prominence as a non-invasive diagnostic tool for various cancers and other diseases. By analyzing epigenetic modifications in circulating DNA and RNA, liquid biopsies can detect early-stage cancer and monitor treatment response with high sensitivity. The integration of AI and machine learning algorithms has accelerated the analysis of vast epigenomic datasets. These technologies can identify subtle patterns and associations in epigenetic data that may be missed by traditional methods, thereby improving diagnostic accuracy. CRISPR-based epigenome editing technologies have enabled precise manipulation of epigenetic marks. While still in the experimental stage, these tools hold great promise for therapeutic interventions in epigenetically driven diseases.

The global epigenetics diagnostics market is experiencing robust growth, driven by these technological advancements. According to market research reports, it is expected to continue expanding at a CAGR of around 18% from 2021 to 2026. This growth is attributed to increased research and development activities, rising awareness of personalized medicine, and the growing demand for non-invasive diagnostic methods. Furthermore, epigenetics diagnostics has the potential to revolutionize disease management by providing more accurate and early-stage diagnostic information. This, in turn, can lead to better treatment strategies, improved patient outcomes, and reduced healthcare costs.

Segmental Insights

Product Insights

Based on the category of Product, Reagents emerged as the dominant player in the global market for Epigenetics Diagnostics in 2022. Reagents, which are chemical substances used to facilitate reactions in scientific experiments and analyses, have emerged as the cornerstone of the epigenetics diagnostics market. They are essential components of various laboratory tests and assays employed in epigenetics research. Reagents are versatile and can be used in a wide range of epigenetic research techniques, including DNA methylation analysis, chromatin immunoprecipitation (ChIP) assays, bisulfite sequencing, and more. This versatility makes reagents indispensable for researchers and clinicians seeking to unravel the complexities of epigenetic regulation. The field of epigenetics is continually evolving, with researchers exploring new techniques and approaches to gain a deeper understanding of epigenetic modifications. This constant innovation drives the demand for specialized reagents tailored to specific research needs. The intense competition among companies operating in the epigenetics diagnostics market has led to continuous advancements in reagent technology. Manufacturers are keen on producing high-quality reagents that offer greater sensitivity, specificity, and ease of use, further solidifying their dominance in the market.

Technology Insights

The DNA methylation segment is projected to experience rapid growth during the forecast period. DNA methylation, in particular, involves the addition of a methyl group to a cytosine base, resulting in the silencing of gene expression in that region. Aberrant DNA methylation patterns have been linked to various diseases, including cancer, neurodegenerative disorders, and cardiovascular diseases. DNA methylation patterns can serve as valuable biomarkers for the early detection and diagnosis of diseases. Researchers have identified specific methylation patterns associated with various cancers, allowing for more accurate and timely diagnoses. Understanding an individual's DNA methylation profile can enable personalized treatment strategies. Tailoring therapies based on a patient's epigenetic profile has the potential to improve treatment outcomes and reduce adverse effects. DNA methylation can be analyzed using non-invasive methods, such as liquid biopsies, which involve the examination of DNA methylation patterns in bodily fluids like blood or urine. This eliminates the need for invasive tissue biopsies, making diagnosis and monitoring more patient friendly.

Regional Insights

North America emerged as the dominant player in the global Epigenetics Diagnostics market in 2022, holding the largest market share in terms of value. North America, particularly the United States, boasts a thriving research and development ecosystem. World-renowned universities, research institutions, and pharmaceutical companies actively invest in epigenetics research. This strong foundation has facilitated the development of cutting-edge epigenetics diagnostic technologies. North America's well-developed healthcare infrastructure and advanced medical facilities have created a conducive environment for the adoption of epigenetics diagnostics. Clinics and hospitals across the region are equipped with state-of-the-art diagnostic equipment and have access to the latest scientific advancements. Public-private collaborations and substantial funding from government agencies and private investors have fueled innovation in epigenetics diagnostics. Initiatives like the National Institutes of Health (NIH) in the United States have played a pivotal role in advancing research in this field.

Key Market Players

Roche Diagnostics

Thermo Fisher Scientific, Inc.

Eisai Co. Ltd.

Novartis AG

Element Biosciences, Inc.

Dovetail Genomics LLC.

Illumina, Inc.

ValiRx Plc.

Abcam plc

Report Scope:

In this report, the Global Epigenetics Diagnostics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Epigenetics Diagnostics Market, By Product:

• Reagents
• Kits
• Instruments
• Enzymes
• Services

Epigenetics Diagnostics Market, By Application:

• Oncology
• Non-oncology

Epigenetics Diagnostics Market, By Technology:

• DNA Methylation
• Histone Methylation
• Histone Acetylation Large noncoding RNA
• MicroRNA modification

Epigenetics Diagnostics Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia-Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE

Competitive Landscape

• Company Profiles: Detailed analysis of the major companies present in the Epigenetics Diagnostics Market.

Available Customizations:

• Global Epigenetics Diagnostics market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Global Epigenetics Diagnostics Market Outlook

• 4.1. Market Size & Forecast
  • 4.1.1. By Value
• 4.2. Market Share & Forecast
  • 4.2.1. By Product (Reagents, Kits (Chip Sequencing Kit, Whole Genomic Amplification kit, Bisulfite Conversion Kit, RNA Sequencing Kit, Others), Instruments, Enzymes, Services)
  • 4.2.2. By Application (Oncology (Solid Tumors, Others), Non-oncology(Inflammatory Diseases, Metabolic Diseases, Infectious Diseases, Cardiovascular Diseases, Others))
  • 4.2.3. By Technology (DNA Methylation, Histone Methylation, Histone Acetylation, Large noncoding RNA, MicroRNA modification)
  • 4.2.4. By Region
  • 4.2.5. By Company (2022)
• 4.3. Market Map
  • 4.3.1. By Product
  • 4.3.2. By Application
  • 4.3.3. By Technology
  • 4.3.4. By Region

5. Asia Pacific Epigenetics Diagnostics Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product
  • 5.2.2. By Application
  • 5.2.3. By Technology
  • 5.2.4. By Country
• 5.3. Asia Pacific: Country Analysis
  • 5.3.1. China Epigenetics Diagnostics Market Outlook
    • 5.3.1.1. Market Size & Forecast
      • 5.3.1.1.1. By Value
    • 5.3.1.2. Market Share & Forecast
      • 5.3.1.2.1. By Product
      • 5.3.1.2.2. By Application
      • 5.3.1.2.3. By Technology
  • 5.3.2. India Epigenetics Diagnostics Market Outlook
    • 5.3.2.1. Market Size & Forecast
      • 5.3.2.1.1. By Value
    • 5.3.2.2. Market Share & Forecast
      • 5.3.2.2.1. By Product
      • 5.3.2.2.2. By Application
      • 5.3.2.2.3. By Technology
  • 5.3.3. Australia Epigenetics Diagnostics Market Outlook
    • 5.3.3.1. Market Size & Forecast
      • 5.3.3.1.1. By Value
    • 5.3.3.2. Market Share & Forecast
      • 5.3.3.2.1. By Product
      • 5.3.3.2.2. By Application
      • 5.3.3.2.3. By Technology
  • 5.3.4. Japan Epigenetics Diagnostics Market Outlook
    • 5.3.4.1. Market Size & Forecast
      • 5.3.4.1.1. By Value
    • 5.3.4.2. Market Share & Forecast
      • 5.3.4.2.1. By Product
      • 5.3.4.2.2. By Application
      • 5.3.4.2.3. By Technology
  • 5.3.5. South Korea Epigenetics Diagnostics Market Outlook
    • 5.3.5.1. Market Size & Forecast
      • 5.3.5.1.1. By Value
    • 5.3.5.2. Market Share & Forecast
      • 5.3.5.2.1. By Product
      • 5.3.5.2.2. By Application
      • 5.3.5.2.3. By Technology

6. Europe Epigenetics Diagnostics Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product
  • 6.2.2. By Application
  • 6.2.3. By Technology
  • 6.2.4. By Country
• 6.3. Europe: Country Analysis
  • 6.3.1. France Epigenetics Diagnostics Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Product
      • 6.3.1.2.2. By Application
      • 6.3.1.2.3. By Technology
  • 6.3.2. Germany Epigenetics Diagnostics Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Product
      • 6.3.2.2.2. By Application
      • 6.3.2.2.3. By Technology
  • 6.3.3. Spain Epigenetics Diagnostics Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Product
      • 6.3.3.2.2. By Application
      • 6.3.3.2.3. By Technology
  • 6.3.4. Italy Epigenetics Diagnostics Market Outlook
    • 6.3.4.1. Market Size & Forecast
      • 6.3.4.1.1. By Value
    • 6.3.4.2. Market Share & Forecast
      • 6.3.4.2.1. By Product
      • 6.3.4.2.2. By Application
      • 6.3.4.2.3. By Technology
  • 6.3.5. United Kingdom Epigenetics Diagnostics Market Outlook
    • 6.3.5.1. Market Size & Forecast
      • 6.3.5.1.1. By Value
    • 6.3.5.2. Market Share & Forecast
      • 6.3.5.2.1. By Product
      • 6.3.5.2.2. By Application
      • 6.3.5.2.3. By Technology

7. North America Epigenetics Diagnostics Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product
  • 7.2.2. By Application
  • 7.2.3. By Technology
  • 7.2.4. By Country
• 7.3. North America: Country Analysis
  • 7.3.1. United States Epigenetics Diagnostics Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product
      • 7.3.1.2.2. By Application
      • 7.3.1.2.3. By Technology
  • 7.3.2. Mexico Epigenetics Diagnostics Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product
      • 7.3.2.2.2. By Application
      • 7.3.2.2.3. By Technology
  • 7.3.3. Canada Epigenetics Diagnostics Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Product
      • 7.3.3.2.2. By Application
      • 7.3.3.2.3. By Technology

8. South America Epigenetics Diagnostics Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product
  • 8.2.2. By Application
  • 8.2.3. By Technology
  • 8.2.4. By Country
• 8.3. South America: Country Analysis
  • 8.3.1. Brazil Epigenetics Diagnostics Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product
      • 8.3.1.2.2. By Application
      • 8.3.1.2.3. By Technology
  • 8.3.2. Argentina Epigenetics Diagnostics Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product
      • 8.3.2.2.2. By Application
      • 8.3.2.2.3. By Technology
  • 8.3.3. Colombia Epigenetics Diagnostics Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product
      • 8.3.3.2.2. By Application
      • 8.3.3.2.3. By Technology

9. Middle East and Africa Epigenetics Diagnostics Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product
  • 9.2.2. By Application
  • 9.2.3. By Technology
  • 9.2.4. By Country
• 9.3. MEA: Country Analysis
  • 9.3.1. South Africa Epigenetics Diagnostics Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product
      • 9.3.1.2.2. By Application
      • 9.3.1.2.3. By Technology
  • 9.3.2. Saudi Arabia Epigenetics Diagnostics Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product
      • 9.3.2.2.2. By Application
      • 9.3.2.2.3. By Technology
  • 9.3.3. UAE Epigenetics Diagnostics Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product
      • 9.3.3.2.2. By Application
      • 9.3.3.2.3. By Technology
  • 9.3.4. Egypt Epigenetics Diagnostics Market Outlook
    • 9.3.4.1. Market Size & Forecast
      • 9.3.4.1.1. By Value
    • 9.3.4.2. Market Share & Forecast
      • 9.3.4.2.1. By Product
      • 9.3.4.2.2. By Application
      • 9.3.4.2.3. By Technology

10. Market Dynamics

• 10.1. Drivers
• 10.2. Challenges

11. Market Trends & Developments

• 11.1. Recent Developments
• 11.2. Product Launches
• 11.3. Mergers & Acquisitions

12. Global Epigenetics Diagnostics Market: SWOT Analysis

13. Porter's Five Forces Analysis

• 13.1. Competition in the Industry
• 13.2. Potential of New Entrants
• 13.3. Power of Suppliers
• 13.4. Power of Customers
• 13.5. Threat of Substitute Product

14. Competitive Landscape

• 14.1. Roche Diagnostics
  • 14.1.1. Business Overview
  • 14.1.2. Company Snapshot
  • 14.1.3. Products & Services
  • 14.1.4. Current Capacity Analysis
  • 14.1.5. Financials (In case of listed)
  • 14.1.6. Recent Developments
  • 14.1.7. SWOT Analysis
• 14.2. Thermo Fisher Scientific, Inc.
• 14.3. Eisai Co. Ltd.
• 14.4. Novartis AG
• 14.5. Element Biosciences, Inc.
• 14.6. Dovetail Genomics LLC.
• 14.7. Illumina, Inc.
• 14.8. ValiRx Plc.
• 14.9. Abcam plc.

15. Strategic Recommendations

16. About Us & Disclaimer